IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/5/2026 | $6.00 | Outperform | Oppenheimer |
Fastest customizable press release news feed in the world
MORRISTOWN, N.J., Feb. 26, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences:TD Cowen 46th Annual Health Care Conference – Dave Lennon, PhD, President and CEO, will participate in a hybrid presentation and fireside chat on Tuesday, March 3 at 10:30 AM ETLeerink 2026 Global Healthcare Conference – executives will participate in investor meetings on Monday, March 9Citizens Life Sciences Conference – Dave Lennon, PhD, President
MORRISTOWN, N.J., Feb. 18, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 8:40 AM EST.A live webcast of the presentation can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.About Whitehawk Therapeutics Whitehawk Therapeutics is a clinical
Actively recruiting Phase 1 trial for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 IND submitted mid-December 2025 for MUC16-targeted ADC HWK-016, anticipated Phase 1 start this quarter Initial clinical data from both programs anticipated in early 2027 MORRISTOWN, N.J., Jan. 8, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for HWK-007, its PTK7-targeted ADC.
Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the appointment of Margaret Dugan, MD, as Chief Medical Officer (CMO). Dr. Dugan brings more than 30 years of global oncology drug development experience, with extensive expertise in early-stage clinical development and regulatory strategy. "I'm delighted to welcome Margaret to Whitehawk. Her strategic insight and
MORRISTOWN, N.J., Nov. 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City, NY on December 3, 2025, at 12:30 PM ET. A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event. About Whitehawk Therapeutics Whitehawk
MORRISTOWN, N.J., Nov. 11, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 11:30 AM GMT. A live webcast of the presentation can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event. About Whitehawk Therapeutics Whitehawk Therapeutics is an oncology therapeutics compan
MORRISTOWN, N.J., Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the third quarter ended September 30, 2025, and provided recent corporate progress. "The third quarter was marked by executional focus, and we remain on track with our planned IND filings for HWK-007 and HWK-016 by the end of the year. We continue to deploy capital efficiently, maintaining strong financial discipline as we prepare to enter the clinic and deliver potentially value-creating miles
PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors PTK7 expression is stable across histologic subtype, disease stage and metastatic status in high-potential indications, including lung, ovarian and endometrial cancers Findings support potential of PTK7 as a pan-tumor target, reinforcing Whitehawk's development of PTK7-directed ADC HWK-007 MORRISTOWN, N.J., Oct. 24, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today prese
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to leverage Tempus' proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics' oncology pipeline. Under the agreement, Whitehawk Therapeutics will apply Tempus' de-identified multimodal database to support the biotech's clinical trial
MORRISTOWN, N.J., Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat during the following upcoming investor conferences in New York City, NY: Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025. Fireside chat at 4:50 PM ET.H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025. Fireside chat at 3:30 PM ET.A live webcast of the fireside chat events can be
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
3 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Oppenheimer initiated coverage of Whitehawk Therapeutics with a rating of Outperform and set a new price target of $6.00
10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
SCHEDULE 13G - Whitehawk Therapeutics, Inc. (0001422142) (Subject)
10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
DEFA14A - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
DEF 14A - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
Live Leadership Updates
Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the appointment of Margaret Dugan, MD, as Chief Medical Officer (CMO). Dr. Dugan brings more than 30 years of global oncology drug development experience, with extensive expertise in early-stage clinical development and regulatory strategy. "I'm delighted to welcome Margaret to Whitehawk. Her strategic insight and